75-18-3

应用筛选条件

关键词:'75-18-3'

显示 1-30 共 2029 条结果关于 "75-18-3" 范围技术文档

单元，最多可安装2个 E-POD® 单元。产水流程示意图供水流程示意图 1 3 4 6 7 11 5 8 10 12 13 14 15 1 自来水进水 17 渗透水电导率传感器 2 进水滤网 18 渗透水三通阀 3 进水电磁阀 19

Single Pass Tangential Flow Filtration (SPTFF)

20% 40% 60% 80% 100% 120% 18-20 g/L 1-sections 18-20 g/L 2-sections 18-20 g/L 3-sections 75 g/L 1-sections 75 g/L 2-sections 75 g/L 3-sections C on ve rs io n Feed lpm

0.0 90 10 1.66 90 10 1.93 75 25 5.54 65 35 8.31 25 75 11.08 25 75 0 60 0 2 4 6 8 10 12 In te Retention time

Single-pass tangential flow filtration

40% 50% 60% 70% 80% 90% 18-20 g/L 2-section 75 g/L 2-section 18-20 g/L 1-section 75 g/L 1-section 18-20 g/L 3-section 75 g/L 3-section 250 200

SMC®Plate Washer Evaluation Kit

49 34 25 18 1 2 61 55 61 72 38 25 67 G 42 10 11 1 25 8 3 32 8 29 54 69 24 22 89 H 55 18 69 23 68 44 63 69

White Paper: Accelerating Cell Line and Process Development

every 2-3 days starting on day 3 0 25 50 75 100 % r et ai n ed t it er mAb 1 Clones 0 25 50 75

Esomeprazole Magnesium (USP) - Delayed Release Capsules Purospher®STAR RP-18 endcapped - Dissolution (Assay)

Pressure Drop: 75 Bar (1080 psi) 40 Esomeprazole Magnesium Capsules (USP) Chromolith® HR RP-18 endcapped - Dissolution (Assay) 0.0 1.0 2.0 3.0 4.0 5.0 0 25 50 75 100 125 150

Product Information Sheet - SEQR

9, add the entirety of the library synthesis reaction to the 75-μL amplification reaction, adjusting water volume (Table 3). Table 3 Input RNA Range 100 pg - 5 ng Intact RNA 1 ng – 50 ng

Data Sheet - C6987

essentially free of other rabbit serum proteins. Anti-Cortactin (GK-18) recognizes human, rat, mouse, and chicken cortactin, (65-75 kDa, 2-3 bands). Applications include the detection of cortactin by immunoblotting

The Effective Use of Protein Kinase Inhibitors

94 89 87 116 91 104 71 50 3 4 13 3 95 78 38 65 34 91 93 96 66 39 93 79 94 103 69 109 20 105 86 90 3 3 96 89 71

Radix Puerariae

.com 12 Radix Puerariae Particle packed column RP-18 endcapped Chromatographic Conditions Column: Particle packed column, RP-18 endcapped (5µm), 250x4.6mm Injection: 10 μl Detection: UV 250

Your first choice - Purospher STAR RP-18 endcapped HPLC column

pieces Purospher® STAR RP-18 endcapped 1.51460.0001 3 µm 75 mm 4 mm 1 piece Purospher® STAR RP-18 endcapped 1.50250.0001 5 µm 4 mm 4 mm 10 pieces Purospher® STAR RP-18 endcapped 1.50251.0001 5 µm 125

Acetaminophen, Aspirin and Caffeine (USP) - Excedrin Tablet Dissolution

than 75% (Q) of the labeled amounts of C8H9NO2, C9H8O4, and C8H10N4O2 is dissolved in 60 min. 17 Acetaminophen, Aspirin and Caffeine (USP) Excedrin Tablet Dissolution 0,E+00 3,E+05

Bcl-w (Minus C-Terminus) human (B1059)

silver staining. Greater than 75% of human Bcl-w elutes at a position corresponding to 18 kDa on size exclusion chromatography, indicating that greater than 75% of recombinant human Bcl-w is monomeric

Pharmaceutical Impurity Profiling Application Guide

to 215 Bar (2320 psi to 3118 psi) Time % A % B 0.01 97 3 10.0 97 3 40 60 y (m V) 22.0 75 25 26.0 97 3 32.0 97

Ultrapure Water for Nano-LCn/MSn Analyses

continuously for 18 hours (> 100 inj.) at a fl ow rate of 0.90 µL/min. The results shown were obtained from a typical nanobore column-emitter confi guration (Waters Atlantis® dC18 (75 µm x 100 mm, 3 µm) AND New

Pharmaceutical impurity profiling Application guide

to 215 Bar (2320 psi to 3118 psi) Time % A % B 0.01 97 3 10.0 97 3 40 60 y (m V) 22.0 75 25 26.0 97 3 32.0 97

User Guide - SAE0176

amino acids 110-660). The DTT-reduced protein migrates as a 80-75 kDa polypeptide on SDS-PAGE because of glycosylation. An additional 3 minor bands of ~ 50 kDa, ~ 37 kDa and ~ 25 kDa may appear. This

Separation of fatty acids

Separation of fatty acids HPTLC Silica gel 60 RP-18 F254s Plate HPTLC pre-coated plate RP-18 254s F (1. 13724) Eluent Ethanol/water 75/20 (v/v) Migration Distance

Letrozole and Related Substances (USP) - Purospher®STAR RP-18 endcapped

STAR RP-18 endcapped Peak Purity curve: Letrozole RS A 0.8 0.9 1.0 32.5 35.0 37.5 40.0 mAU Peak Zero Line Purity Curve UV spectra: Letrozole RS A 65 70

The Effective Use of Protein Kinase Inhibitors

94 89 87 116 91 104 71 50 3 4 13 3 95 78 38 65 34 91 93 96 66 39 93 79 94 103 69 109 20 105 86 90 3 3 96 89 71

Datasheet-HS234525R